Genetically Determined Risk of Depression and Functional Outcome After Ischemic Stroke.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 27 6 2019
medline: 10 3 2020
entrez: 27 6 2019
Statut: ppublish

Résumé

Background and Purpose- Psychosocial factors can have implications for ischemic stroke risk and recovery. This study investigated the effect of genetically determined risk of depression on these outcomes using the Mendelian randomization (MR) framework. Methods- Genetic instruments for risk of depression were identified in a discovery genome-wide association study of 246 363 cases and 561 190 controls and further replicated in a separate population of 474 574 cases and 1 032 579 controls. Corresponding genetic association estimates for risk of ischemic stroke were taken from 60 341 cases and 454 450 controls, with those for functional outcome 3 months after ischemic stroke taken from an analysis of 6021 patients. Following statistical power calculation, inverse-variance weighted MR was performed to pool estimates across different instruments. The Cochran Q heterogeneity test, weighted median MR, and MR pleiotropy residual sum and outlier were used to explore possible bias relating to inclusion of pleiotropic variants. Results- There was no MR evidence for an effect of genetically determined risk of depression on ischemic stroke risk. Although suffering low statistical power, the main inverse-variance weighted MR analysis was suggestive of a detrimental effect of genetically determined risk of depression on functional outcome after ischemic stroke (odds ratio of poor outcome [modified Rankin Scale, ≥3] per 1-SD increase in genetically determined risk of depression, 1.81; 95% CI, 0.98-3.35; P=0.06). There was no evidence of heterogeneity between MR estimates produced by different instruments (Q P=0.26). Comparable MR estimates were obtained with weighted median MR (odds ratio, 2.57; 95% CI, 1.05-6.25; P=0.04) and MR pleiotropy residual sum and outlier (odds ratio, 1.81; 95% CI, 0.95-3.46; P=0.08). Conclusions- We found no MR evidence of genetically determined risk of depression affecting ischemic stroke risk but did find consistent MR evidence suggestive of a possible effect on functional outcome after ischemic stroke. Given the widespread prevalence of depression-related morbidity, these findings could have implications for prognostication and personalized rehabilitation after stroke.

Identifiants

pubmed: 31238828
doi: 10.1161/STROKEAHA.119.026089
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2219-2222

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS086905
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS082285
Pays : United States

Auteurs

Dipender Gill (D)

From the Department of Epidemiology and Biostatistics, School of Public Health (D.G.), Imperial College London, United Kingdom.

Nicole E James (NE)

Faculty of Medicine (N.E.J., G.M.), Imperial College London, United Kingdom.

Grace Monori (G)

Faculty of Medicine (N.E.J., G.M.), Imperial College London, United Kingdom.

Erik Lorentzen (E)

Bioinformatics Core Facility, University of Gothenburg, Sweden (E.L.).

Israel Fernandez-Cadenas (I)

Stroke Pharmacogenomics and Genetics, Institut d'investigació Biomedica de Sant Pau, Hospital de Sant Pau, Barcelona, Spain (I.F.-C.).
Department of Neurology (I.F.-C.), Neurovascular Research Laboratory and Neurovascular Unit, Universitat Autònoma de Barcelona, Vall d'Hebrón Hospital, Spain.
Department of Medicine (I.F.-C.), Neurovascular Research Laboratory and Neurovascular Unit, Universitat Autònoma de Barcelona, Vall d'Hebrón Hospital, Spain.

Robin Lemmens (R)

Department of Neurosciences, Experimental Neurology, University of Leuven, Belgium (R.L.).
Center for Brain and Disease Research, Laboratory of Neurobiology, Leuven, Belgium (R.L.).
Department of Neurology, University Hospitals Leuven, Belgium (R.L.).

Vincent Thijs (V)

Stroke Division, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Australia (V.T.).
Department of Neurology, Austin Health, Heidelberg, Australia (V.T.).

Natalia S Rost (NS)

Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (N.S.R.).

Rodney Scott (R)

School of Medicine and Public Health (R.S.), University of Newcastle, Australia.
Hunter Medical Research Institute (R.S., J.M.M.), University of Newcastle, Australia.

Graeme J Hankey (GJ)

Medical School, The University of Western Australia, Perth (G.J.H.).

Arne Lindgren (A)

Department of Neurology and Rehabilitation Medicine, Neurology, Skåne University Hospital, Lund, Sweden (A.L.).
Department of Clinical Sciences Lund, Neurology, Lund University, Sweden (A.L.).

Christina Jern (C)

Department of Clinical Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Sweden (C.J.).

Jane M Maguire (JM)

Hunter Medical Research Institute (R.S., J.M.M.), University of Newcastle, Australia.
University of Technology Sydney, Faculty of Health, Sydney, Australia (J.M.M.).
Priority Research Centre for Stroke and Traumatic Brain Injury, University of Newcastle, Australia (J.M.M.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH